These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9347201)

  • 1. The effect of flumazenil on subclinical psychometric or neurophysiological alterations in cirrhotic patients: a double-blind placebo-controlled study.
    Amodio P; Marchetti P; Del Piccolo F; Beghi A; Comacchio F; Carraro P; Campo G; Baruzzo L; Marchiori C; Gatta A
    Clin Physiol; 1997 Sep; 17(5):533-9. PubMed ID: 9347201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flumazenil in cirrhotic patients in hepatic coma: a randomized double-blind placebo-controlled crossover trial.
    Pomier-Layrargues G; Giguère JF; Lavoie J; Perney P; Gagnon S; D'Amour M; Wells J; Butterworth RF
    Hepatology; 1994 Jan; 19(1):32-7. PubMed ID: 8276366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visual event-related potentials in cirrhotic patients without overt encephalopathy: the effects of flumazenil.
    Jones EA; Giger-Mateeva VI; Reits D; Riemslag FC; Liberov B; Spekrijse H
    Metab Brain Dis; 2001 Jun; 16(1-2):43-53. PubMed ID: 11726088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flumazenil in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double blind randomized placebo controlled study.
    Laccetti M; Manes G; Uomo G; Lioniello M; Rabitti PG; Balzano A
    Dig Liver Dis; 2000 May; 32(4):335-8. PubMed ID: 11515632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased brain concentrations of endogenous (non-benzodiazepine) GABA-A receptor ligands in human hepatic encephalopathy.
    Ahboucha S; Pomier-Layrargues G; Butterworth RF
    Metab Brain Dis; 2004 Dec; 19(3-4):241-51. PubMed ID: 15554420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flumazenil for hepatic coma in patients with liver cirrhosis: an Italian multicentre double-blind, placebo-controlled, crossover study.
    Barbaro G; Di Lorenzo G; Soldini M; Marziali M; Bellomo G; Belloni G; Grisorio B; Annese M; Bacca D; Barbarini G
    Eur J Emerg Med; 1998 Jun; 5(2):213-8. PubMed ID: 9846248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evoked potentials and the effect of flumazenil in patients with liver cirrhosis.
    Ozyilkan E; Kahraman H; Onar M; Kesim G; Arik Z
    East Afr Med J; 1997 Apr; 74(4):210-2. PubMed ID: 9299818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: an Italian multicenter double-blind, placebo-controlled, cross-over study.
    Barbaro G; Di Lorenzo G; Soldini M; Giancaspro G; Bellomo G; Belloni G; Grisorio B; Annese M; Bacca D; Francavilla R; Barbarini G
    Hepatology; 1998 Aug; 28(2):374-8. PubMed ID: 9695999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flumazenil therapy for hepatic encephalopathy in cirrhotic patients: a double-blind pragmatic randomized, placebo study.
    Cadranel JF; el Younsi M; Pidoux B; Zylberberg P; Benhamou Y; Valla D; Opolon P
    Eur J Gastroenterol Hepatol; 1995 Apr; 7(4):325-9. PubMed ID: 7600138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benzodiazepine receptor antagonism improves reaction time in latent hepatic encephalopathy.
    Gooday R; Hayes PC; Bzeizi K; O'Carroll RE
    Psychopharmacology (Berl); 1995 Jun; 119(3):295-8. PubMed ID: 7675964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased risk of cognitive impairment in cirrhotic patients with bacterial infections.
    Merli M; Lucidi C; Pentassuglio I; Giannelli V; Giusto M; Di Gregorio V; Pasquale C; Nardelli S; Lattanzi B; Venditti M; Riggio O
    J Hepatol; 2013 Aug; 59(2):243-50. PubMed ID: 23523580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of flumazenil on visual event-related potentials of clinically non-encephalopathic patients with cirrhosis.
    Giger-Mateeva VI; Reits D; Liberov B; Jones EA; Spekreijse H
    Neurosci Lett; 1999 Dec; 276(3):173-6. PubMed ID: 10612633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy.
    Goh ET; Andersen ML; Morgan MY; Gluud LL
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD002798. PubMed ID: 28745801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benzodiazepine antagonist in the treatment of human hepatic encephalopathy.
    Ferenci P; Grimm G
    Adv Exp Med Biol; 1990; 272():255-65. PubMed ID: 2103692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of flumazenil in subclinical to mild hepatic encephalopathic ambulatory patients. A prospective, randomised, double-blind, placebo-controlled study.
    Dursun M; Caliskan M; Canoruc F; Aluclu U; Canoruc N; Tuzcu A; Yilmaz S; Isikdogan A; Ertem M
    Swiss Med Wkly; 2003 Feb; 133(7-8):118-23. PubMed ID: 12644958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benzodiazepine receptor antagonists for acute and chronic hepatic encephalopathy.
    Als-Nielsen B; Kjaergard LL; Gluud C
    Cochrane Database Syst Rev; 2001; (4):CD002798. PubMed ID: 11687160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of the behavioral and electrophysiological abnormalities of an animal model of hepatic encephalopathy by benzodiazepine receptor ligands.
    Gammal SH; Basile AS; Geller D; Skolnick P; Jones EA
    Hepatology; 1990 Mar; 11(3):371-8. PubMed ID: 2155865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical features and survivial of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests.
    Amodio P; Del Piccolo F; Marchetti P; Angeli P; Iemmolo R; Caregaro L; Merkel C; Gerunda G; Gatta A
    Hepatology; 1999 Jun; 29(6):1662-7. PubMed ID: 10347105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diazepam-induced disruption of classically-conditioned fear-potentiation of late-latency auditory evoked potentials is prevented by flumazenil given before, but not after, CS/US pairing.
    Scaife JC; Hou RH; Samuels ER; Baqui F; Langley RW; Bradshaw CM; Szabadi E
    J Psychopharmacol; 2007 Jan; 21(1):93-101. PubMed ID: 16533870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flumazenil therapy for hepatic encephalopathy. A double-blind cross over study.
    Van der Rijt CC; Schalm SW; Meulstee J; Stijnen T
    Gastroenterol Clin Biol; 1995; 19(6-7):572-80. PubMed ID: 7590022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.